GET DAILY SIGNALSOpus Genetics (IRD): Weighing the Path to the $13 Analyst Target
Key Takeaways
- The central target used here is $13, the rounded arithmetic mean of the verified analyst price targets reviewed, not an official published consensus.
- The latest verified price is roughly $4.31, meaning the target implies a move of about 200% — a very large required advance.
- Approximately 18 analysts cover the stock, with individual targets spanning a wide range from about $7 to $20, and ratings are overwhelmingly Buy or Outperform.
- The strongest support comes from gene therapy pipeline catalysts, including a fully enrolled Phase 3 trial and near-term data readouts.
- The biggest risks are a thin revenue base, recurring net losses, and the binary nature of clinical-stage biotech outcomes.
- For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
Analyst Price Targets and Consensus View
Analyst coverage of IRD is broad but spread across a notably wide band. Targets reviewed from the second half of 2026 range from roughly $7 to $20, with the arithmetic mean landing near $13. Independent trackers report similar figures — averages around $12.70 to $13.60 depending on the analyst set — which is consistent with a rounded central target of $13. Importantly, this $13 figure is the average of individual targets, not a guarantee, and no single analyst owns it.
The dispersion explains a great deal. More cautious estimates include H.C. Wainwright at $8 and RBC Capital at $9, while more bullish calls come from Oppenheimer at $20, Citizens JMP at $17, and JonesTrading at $17. Mid-range targets include Wedbush at $13, BTIG at $12, Leerink Partners at $15, and Chardan Capital at $16. Ratings are uniformly Buy, Outperform, or Overweight among the sell-side analysts who publish price targets, with the only cautionary voices coming from quantitative rating systems rather than target-setting equity analysts.
The reasoning behind the bullish stance centers on the company's gene therapy pipeline and FDA alignment, while the low end of the range reflects the inherent execution and clinical risk of a pre-revenue biotech. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares trading around $4.31, reaching $13 would require a gain of roughly 200% — a very large move by any standard, even for a volatile small-cap biotech. Such a move would depend on a sustained re-rating driven by clinical data and regulatory progress rather than incremental news flow.
The company reported third-quarter 2026 license and collaboration revenue of $1.1 million and a net loss of $46.5 million, or $0.46 per share, with cash and cash equivalents of $89.0 million as of September 30, 2026. A $155 million strategic financing agreement with Oberland Capital, secured earlier in 2026, provides additional runway. The market capitalization sits around $300 million, so the path to $13 would require the pipeline's value to be substantially re-priced as programs advance.
What Could Support a Move Toward the Target
The most material catalysts are clinical. The OPGx-LCA5 registrational Phase 3 trial is fully enrolled, with dosing expected to begin in the fourth quarter of 2026. The OPGx-BEST1 Phase 1/2 program completed dosing in its high-dose cohort, with topline data anticipated in the first quarter of 2027. The FDA also cleared an investigational new drug application for OPGx-RDH12, with Phase 1/2 dosing planned. Favorable data readouts or regulatory milestones could meaningfully re-rate the shares.
Additionally, FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia triggered a milestone payment from partner Viatris, offering non-dilutive upside. A broad AAV (adeno-associated virus) gene therapy platform addressing multiple retinal conditions underpins the long-term thesis. From what I see, these upcoming readouts are the key variables that could shift sentiment.
What Could Prevent the Target From Being Reached
IRD remains a clinical-stage company with minimal revenue and steep ongoing losses. Clinical trials — particularly in gene therapy — carry binary risk, and disappointing or mixed data, safety signals, or regulatory setbacks could sharply compress the valuation. The company's negative gross margin and large net losses mean it is likely to require additional capital over time, which could dilute existing shareholders. Competition in ophthalmic gene therapy is intensifying, and the stock's own one-year gain of well over 100% already prices in substantial optimism. A broader risk-off rotation away from speculative biotech, or any financing overhang, could also weigh on the shares.
Technical Levels and Market Structure
The stock's 52-week range runs from roughly $1.22 to $5.81, reflecting extraordinary volatility. After a sharp rally, shares sit below that prior high, leaving the $5 area and the 52-week high near $5.81 as the nearest meaningful resistance zones to clear before a move toward $13 could be contemplated. On the downside, the prior multi-dollar range below $4 represents the structural support area. Given the wide price swings, the stock's trend structure remains one of high beta rather than steady accumulation.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, and the figures cited here follow that convention, though individual analysts may differ. Investors should watch the OPGx-LCA5 Phase 3 dosing start, the OPGx-BEST1 topline data expected in the first quarter of 2027, and the OPGx-RDH12 Phase 1/2 initiation. Quarterly cash burn, financing activity, analyst target revisions, and any FDA or regulatory updates are the key near-term variables. Given the binary nature of the pipeline, data readouts — not earnings — are likely to be the dominant drivers of the stock.
Using AI Tools for Ongoing Monitoring
For traders looking to track changing conditions in real time, Tickeron's AI Daily Buy/Sell Signals provide a systematic way to monitor sentiment shifts. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. This can help traders spot opportunities, monitor existing positions, and identify changing trends more efficiently than manual screening alone. I find it useful as one input alongside my own research when evaluating IRD, particularly around clinical milestones.
Final Assessment
The $13 central target reflects the average of a wide analyst range — roughly $7 to $20 — rather than any single forecast. With shares near $4.31, reaching that level would require a very large advance of around 200%, a move that hinges almost entirely on successful clinical execution and favorable data readouts rather than incremental financial progress. The bullish case rests on a fully enrolled Phase 3 program, near-term catalysts, and a broad gene therapy platform, while the bearish case points to thin revenue, recurring losses, financing risk, and binary clinical outcomes. Analyst agreement on direction is strong, but the wide target dispersion underscores genuine uncertainty about magnitude. Investors should monitor the upcoming clinical milestones closely, as they are likely to determine whether $13 is reachable.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRD in +1.20% Uptrend, growing for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IRD advanced for three days, in 215 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IRD's RSI Oscillator exited the oversold zone, 18 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on IRD as a result. In 89 of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for IRD just turned positive on November 03, 2026. Looking at past instances where IRD's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
IRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IRD moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IRD crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for IRD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-26.779) is normal, around the industry mean (3.498). P/E Ratio (-3.240) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics
Industry Biotechnology
Advertisement